Comparative Outcomes of Brachyury Vaccine vs. Imatinib in Advanced Chordoma: A Mayo Clinic Experience.

Cancers (Basel) · 2025 · PMC12609630 · PMID 41228286

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although statistical significance was not reached ( p = 0.059), likely due to the small sample size, imatinib showed a trend toward improved TTP after initiation of therapy when compared with the BRACHY-001 trial vaccines.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.